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Reviewers' comments:  
 
Reviewer #1 (Remarks to the Author):  
 
 
This manuscript by Young et al proposes a new algorithm for jointly clustering and staging 
of patients suffering from a neurodegenerative condition. The underlying assumption is that 
amongst a set of imaging biomarkers, there is a sequence of events at which each 
biomarker becomes abnormal. The idea of inferring such a sequence for each cluster, along 
with detecting the clusters themselves, is a very nice if ambitious idea. The authors propose 
a likelihood function whose maximization is attempted using a set of heuristics within an 
expectation maximization (EM) framework.  
 
The strength of the paper is that the problem is cast in a sophisticated statistical way, and 
inference involves an equally sophisticated, if somewhat arbitrary, sampling approach. The 
key results suggest there are 4 subtypes in FTD and 3 in AD, each with a well defined 
temporal progression. These are likely to be very important contributions to the field, if 
true. I also really liked the principled statistical thinking behind the approach and the 
ambition of solving such a challenging problem.  
 
However there are many weaknesses that reduce enthusiasm, as listed below.  
 
1. The underlying model of temporal evolution is not well motivated. Why should a bunch of 
imaging biomarkers follow a set of discrete “stages”? I am not saying this is wrong, just 
needs to be justified more convincingly. How are the event thresholds specified, and on 
what basis? If the goal is to develop a joint subtype and stage model, the current one 
“seems” (admittedly with no supporting evidence) to be needlessly high dimensional. Can 
the temporal trajectory of each subtype not be parametrized by a low dimensional curve, eg 
polynomial?  
 
2. Biomarkers are treated as independent of each other, which is at variance with mounting 
evidence in the field. Different brain regions are connected to each other and pathological 
progression is known to have a stereotyped and well ordered pattern of spatiotemporal 
spread. By treating each brain region’s atrophy as basically independent, are you losing 
valuable information that could otherwise have been quite powerful in the inference 
process?  
 
3. The priors used are pretty uninformative (uniform distributions), and this is at variance to 
what we already known in the field. Biomarkers are not independent of each other, and 
perhaps a joint prior or covariance can be specified. At the very least, a Bayesian or Aikike 
information criterion can and should be added to the model likelihood in order to ensure 
that the smallest feasible set of parameters is fitted. 
 
4. The optimization procedure (heuristic), while sophisticated and thorough, is quite 
arbitrary ad hoc and greedy. From my reading the overall algorithm would seem to have no 
optimality or convergence guarantees, and it is unclear whether there is a global minimum 
or a small set of local minima that can be reached by it. There are several combinatorial 
algorithms with some global optimality properties that could be adapted to solve the present 
cost function, instead of a mishmash of random initializations, greedy EM and MCMC. Again, 
I am not doubting that the presented approach works, simply that it is not clear how well it 
works. From a practical standpoint, proposing a sophisticated likelihood function to be 
maximized is only half of the job; developing a principled and well-justified algorithm to 
solve it is equally important. At no point did I get the sense that the authors have 
thoughtfully considered their algorithmic options and chosen the most suitable ones.  
 
1. Methods:  
1. Why are only MR imaging-derived biomarkers specific to atrophy considered in the 
model? This is quite surprising, since ADNI and I assume GENFI data have multiple PET 
scans (FDG, PiB, AV45, etc), each of which is a critical biomarker.  
2. Although I am mindful that the authors wish to minimize the dimensionality of the 
problem, it seems quite limiting that only 6 gross regions are considered (frontal, parietal, 
temporal, occipital, insult and cingulate). What about other important regions like the 
striatum, hippocampus, entorhinal, cerebellum, etc? Other studies in the field typically 
present far more regional data (86 in Desikan atlas, 116 in AAL, etc).  
3. The method section needs more specificity. Perhaps a table will be useful that contains a 
list of all relevant quantities and symbols mentioned in the text, their operating range and 
their initial estimates. List all the biomarkers individually. It is frustrating that the values of 
R_i, I, N, z_max, C_max, etc are not readily accessible in the manuscript.  
4. I think a flowchart of the full algorithm will also aid understanding and readability, as 
there are multiple heuristics and MCMC sampling steps.  
 
2. Results:  
1. Although comprehensive data and statistical analyses were presented, it was still difficult 
to have full confidence in the key findings (4 clusters in GENFI, 3 in AD). I also appreciate 
the attempt to provide context by comparing the results to a stages-only and a subtype-
only model. Partly, this is eh nature of the problem, where a gold standard is simply not 
available. However, several approaches could have been taken to help place the results in 
context and improve confidence that what we are seeing is real. Some thoughts are below.  
2. A simulation exercise should be undertaken, where artificial biomarker trajectories could 
be constructed using the likelihood function proposed, and then add relevant noise and 
other uncertainties. It would be convincing if the inference algorithm could correctly 
estimate all clusters and stages on this artificial data. In such an approach error rates, MSE, 
AUC etc can be readily calculated.  
3. Similar to #3 above, a plot of performance with respect to increasing dimensionality (e.g. 
cluster number, number of temporal events N, etc) should be given, and an objective 
criterion of model evidence (e.g. Bayesian or Aikike information, MDL, etc) provided. This 
will help the reader understand, for instance, what is the level of evidence supporting the 
existence of exactly 4 clusters in GENFI and exactly 3 in AD. What happens when you 
change other hard-wired parameters (N, I, C_max)?  
4. Identifiability: this term was used in too loose a sense, in my opinion, based simply on 
Fig 5. There are numerical measures of identifiability that should be reported, if indeed the 
authors wish to claim this point.  
 In summary, the present work is potentially a very important contribution to the field of 
neuroimaging and neurodegeneration, but several aspects require better justification and a 
more thorough exercising of the results. In view of these points, I would consider its impact 




Reviewer #3 (Remarks to the Author):  
 
The authors apply machine learning to MRI datasets obtained from patients diagnosed with 
FTD and AD. They appear to have generated a model that will distinguish the various 
genetic forms of FTD from each other, and the various subtypes of AD from each other. 
They also claim to identify two subtypes within one genetic form of FTD relating to the rate 
of progression. Overall, while I do find that there are some potentially useful pieces of 
information in this manuscript, it is rather densely presented meaning that it may not have 
appeal to the general reader and may be more appropriate in a more specialized journal.  
 
There are aspects of this manuscript that do not reflect the typical clinical scenario. For 
example, they use MRI to identify subjects carrying specific mutations, but most patients 
are genetically screened for these mutations at the time of presentation, so it is not clear 
how useful it would be to apply this machine learning approach to identify genetic mutations 
carriers when either this information is already known or can be much more easily obtained 
by doing a simple genetic test. Thus, the clinical utility of this approach is unclear.  
 
The authors may be overstating the novelty of their data. It has long been known that GRN 
mutations produce an asymmetrical pattern of atrophy, that MAPT mutations affect 
temporal lobes (usually not as asymmetrically), and that C9orf72 related findings are 
typically widespread and affect cortex and subcortical structures.  
 
It is sometimes difficult to follow exactly what the authors did. For example, it is not clear 
how many samples were analyzed by their algorithm to generate their model. Did they 
include normal, pre-symptomatic, or was it just confined to symptomatic cases? These 
numbers should be include in the first paragraph of the Results section. However, even if all 
cases were included, then the number of symptomatic cases is still small (e.g. 14 patients 
carrying GRN mutations, 24 patients carrying C9, 11 MAPT, 117 AD cases). This is likely too 
small to generate robust results.  
 
With respect to the 117 AD cases, was the diagnosis established pathologically for all of 
them? It is known that the clinical diagnosis of AD is inaccurate in 15% of cases, so if the 
diagnosis of AD was based on clinical presentation, did you allow for this inaccuracy in your 
model?  
 
The programming code used to generate the model as well as the final model should be 
made available in the supplemental material so that others can test it and add to it as more 
data becomes available.  
We thank the reviewers for their detailed feedback on the manuscript. 
Addressing their concerns has substantially improved the readability of the 
manuscript for a general audience, and substantiated the validity of the 
results. In response to Reviewer 1’s concerns over validity of the 
methodology, we now include a detailed simulation study investigating 
convergence properties and the effect of the quantities suggested by the 
reviewer. We have further revised the methods section substantially to 
improve clarity, with the aid of the flow charts and tables suggested by the 
reviewer. In response to Reviewer 3 we have revised the manuscript to 
improve readability for a general audience, clarified the validation role of 
GENFI, and more generally adapted the text to ensure the novelty and clinical 





Reviewer #1 (Remarks to the Author): 
  
  
This manuscript by Young et al proposes a new algorithm for jointly clustering 
and staging of patients suffering from a neurodegenerative condition. The 
underlying assumption is that amongst a set of imaging biomarkers, there is a 
sequence of events at which each biomarker becomes abnormal. The idea of 
inferring such a sequence for each cluster, along with detecting the clusters 
themselves, is a very nice if ambitious idea. The authors propose a likelihood 
function whose maximization is attempted using a set of heuristics within an 
expectation maximization (EM) framework. 
  
The strength of the paper is that the problem is cast in a sophisticated 
statistical way, and inference involves an equally sophisticated, if somewhat 
arbitrary, sampling approach. The key results suggest there are 4 subtypes in 
FTD and 3 in AD, each with a well defined temporal progression. These are 
likely to be very important contributions to the field, if true. I also really liked 
the principled statistical thinking behind the approach and the ambition of 
solving such a challenging problem. 
  
However there are many weaknesses that reduce enthusiasm, as listed 
below. 
  
1. The underlying model of temporal evolution is not well motivated. Why 
should a bunch of imaging biomarkers follow a set of discrete “stages”? I am 
not saying this is wrong, just needs to be justified more convincingly. How are 
the event thresholds specified, and on what basis? If the goal is to develop a 
joint subtype and stage model, the current one “seems” (admittedly with no 
supporting evidence) to be needlessly high dimensional. Can the temporal 
trajectory of each subtype not be parametrized by a low dimensional curve, eg 
polynomial? 
  
R1.1. In fact, SuStaIn models imaging biomarkers as following piecewise 
linear trajectories; a very similar idea to the polynomial trajectories the 
reviewer suggests. Moreover, SuStaIn requires no explicit “event thresholds”, 
but infers the stage ordering probabilistically. The dimensionality is low - just a 
few linear segments per biomarker (up to a maximum of four in this work) – 
and comparable to that of the suggested polynomial model. However, the 
unique advantage of dividing the trajectories up into stages is that it enables 
modeling of purely cross-sectional data where the timescale of change is hard 
if not impossible to estimate. This makes the resulting model practical in 
clinical scenarios by enabling it to assign subtype and stage to individuals at 
their first visit. We have rewritten relevant parts of the Methods (see Methods: 
Mathematical modeling: lines 627-630) and Discussion (see Discussion: 
Model assumptions and limitations: lines 502-507) to clarify these points. 
  
2. Biomarkers are treated as independent of each other, which is at variance 
with mounting evidence in the field. Different brain regions are connected to 
each other and pathological progression is known to have a stereotyped and 
well ordered pattern of spatiotemporal spread. By treating each brain region’s 
atrophy as basically independent, are you losing valuable information that 
could otherwise have been quite powerful in the inference process? 
  
R1.2. First, to clarify, the biomarkers are not independent under the SuStaIn 
model because they co-evolve over time. However, a related assumption, 
which perhaps the reviewer refers to, is that the biomarker variance is 
assumed independent. This is an assumption common to almost all current 
disease progression models and is necessary to keep the dimensionality of 
the problem under control.  
We do agree that real world data likely violates this assumption and have now 
commented on this in the manuscript – see Discussion: Model Assumptions 
lines 494-497. To demonstrate the validity of the modelling in the presence of 
biomarker covariance we have performed a simulation study – see 
Supplementary Material – assessing the effect of different levels of biomarker 
covariance on the accuracy of the subtype progression patterns recovered by 
SuStaIn (see Figure S7). The effect is subtle and does not affect gross 
findings such as the presence and broad characteristics of subtypes.  
  
3. The priors used are pretty uninformative (uniform distributions), and this is 
at variance to what we already known in the field. Biomarkers are not 
independent of each other, and perhaps a joint prior or covariance can be 
specified. At the very least, a Bayesian or Aikike information criterion can and 
should be added to the model likelihood in order to ensure that the smallest 
feasible set of parameters is fitted. 
  
R.1.3. This is a misunderstanding. The uniform prior is on disease stage and 
does not relate to biomarker independence. This prior is reasonable given that 
the subject-stage is one of the parameters we estimate – the uniform prior 
adds the least information possible and avoids circularity. With regards to 
using Bayesian or Akaike information criterion for model selection, we chose 
to use cross-validation, which does the same job, but is better at penalising 
complexity – see the Gelman reference in the manuscript. We have adapted 
the Methods to clarify the role of the prior – see lines 650-652 – and that 
cross-validation performs the role of model selection – see lines 688-690 and 
755-757. 
The reviewer’s suggestion that one might use model selection (AIC, BIC, or 
cross validation) to select which biomarker covariances a model might need to 
include is an interesting idea, but beyond the scope of the current work. We 
now refer to the possibility in the Discussion (lines 498-500). 
  
4. The optimization procedure (heuristic), while sophisticated and thorough, is 
quite arbitrary ad hoc and greedy. From my reading the overall algorithm 
would seem to have no optimality or convergence guarantees, and it is 
unclear whether there is a global minimum or a small set of local minima that 
can be reached by it. There are several combinatorial algorithms with some 
global optimality properties that could be adapted to solve the present cost 
function, instead of a mishmash of random initializations, greedy EM and 
MCMC. Again, I am not doubting that the presented approach works, simply 
that it is not clear how well it works. From a practical standpoint, proposing a 
sophisticated likelihood function to be maximized is only half of the job; 
developing a principled and well-justified algorithm to solve it is equally 
important. At no point did I get the sense that the authors have thoughtfully 
considered their algorithmic options and chosen the most suitable ones. 
  
R1.4. The optimisation procedure extends a well-established procedure, 
proposed in Fonteijn et al. Neuroimage 2012, further developed in Young et 
al. Brain 2014, and applied in a range of subsequent publications on the 
event-based model (Oxtoby et al. Brain 2018, Wijeratne et al. Annals of 
Clinical and Translational Neurology 2018, Eshaghi et al. Brain 2018) to the 
case of multiple distinct progression patterns. In light of the reviewer’s 
comment we have now revised the manuscript to include a simulation study 
demonstrating convergence and optimality of the algorithm – see 
Supplementary Material S1.2.1 – initially excluded for succinctness and 
appeal to a broad readership. The simulations show very strong convergence 
and optimality properties, i.e. the EM reliably converges to the global 
minimum. The purpose of the MCMC is to sample the posterior distribution on 
the model parameters once the EM finds the maximum likelihood solution; the 
simulations further demonstrate that estimates of features of the posterior 
distribution behave sensibly. 
With respect, we do not agree that standard combinatorial algorithms adapt 
naturally to the optimization task we face here, which simultaneously 
optimizes subtype membership, subtype trajectory, and the posterior 
distributions of both. In particular, the cost function here depends on the 
ordering of a sequence of control points in multiple piecewise linear 
trajectories (the “events”), which standard algorithms do not handle. We are 
very happy to be corrected on this point if the reviewer is aware of a specific 
algorithm for such a task. However, even if such an algorithm does exist, its 
usage would not affect the findings we report, only reduce the computation 
time required to obtain them. We add these thoughts to Methods: 
Mathematical modelling: Model fitting, see lines 681-687. 
  
1. Methods: 
1. Why are only MR imaging-derived biomarkers specific to atrophy 
considered in the model? This is quite surprising, since ADNI and I assume 
GENFI data have multiple PET scans (FDG, PiB, AV45, etc), each of which is 
a critical biomarker. 
  
R1.5. We chose to focus on MRI biomarkers alone for a number of reasons:  
1. Foremost, sample size. The inclusion of any of the suggested  additional 
biomarkers would reduce the number of available subjects to  less than 
half.   
2. Simplicity. MRI alone proves sufficient to demonstrate the capability  and 
potential of subtyping with SuStaIn and reveals new knowledge in its 
own right. Addition of more data types could very well reveal additional 
and/or refined subtypes, but complicates the message of a paper that 
already contains substantial novelty. Thus, we prefer to leave such 
exploration for future work.   
3. Finally, clinical utility. Using a single modality has great advantage in the 
clinical scenario by enabling subtype assignment using (cheap and 
harmless) MRI alone rather than a complex combination of modalities 
requiring the use of radiotracers and expensive PET scanners.   
We have added these arguments to the manuscript (see Discussion: Disease 
subtyping and staging: Utility of SuStaIn subtypes and stages – lines 482-
484), as well as discussion of the potential for the inclusion of additional 
markers in future work (see Discussion: Disease subtyping and staging: Utility 
of SuStaIn subtypes and stages – lines 484-486).  
  
2. Although I am mindful that the authors wish to minimize the dimensionality 
of the problem, it seems quite limiting that only 6 gross regions are considered 
(frontal, parietal, temporal, occipital, insult and cingulate). What about other 
important regions like the striatum, hippocampus, entorhinal, cerebellum, etc? 
Other studies in the field typically present far more regional data (86 in 
Desikan atlas, 116 in AAL, etc). 
  
R1.6. In part there is a misunderstanding here – subcortical regions are 
included in addition to the 6 larger regions mentioned by the reviewer. As the 
reviewer points out, increasing biomarkers numbers increases the 
dimensionality, which complicates model estimation. Since the relatively small 
number of regions proves sufficient to identify and distinguish subtypes, we 
see no reason to complicate the analysis with more regions/biomarkers in this 
initial study. In future, we do plan to include a larger number of regions, as 
well as additional markers, having first demonstrated validity of the technique 
in a lower dimensional scenario. We now make this point in lines 484-486. 
  
3. The method section needs more specificity. Perhaps a table will be useful 
that contains a list of all relevant quantities and symbols mentioned in the text, 
their operating range and their initial estimates. List all the biomarkers 
individually. It is frustrating that the values of R_i, I, N, z_max, C_max, etc are 
not readily accessible in the manuscript. 
  
R1.7. We have added two tables detailing the quantities suggested by the 
reviewer – see Supplementary Material – Tables S3 and S4 and Methods – 
Experiments – Lines 826-827. 
  
 
4. I think a flowchart of the full algorithm will also aid understanding and 
readability, as there are multiple heuristics and MCMC sampling steps. 
  
R1.8. Thank you for this suggestion. We have added a flowchart of the full 
algorithm to the manuscript – see Supplementary Material – Figure S15 and 
updated the Methods section to make the description of the algorithm clearer 




1. Although comprehensive data and statistical analyses were presented, it 
was still difficult to have full confidence in the key findings (4 clusters in 
GENFI, 3 in AD). I also appreciate the attempt to provide context by 
comparing the results to a stages-only and a subtype-only model. Partly, this 
is eh nature of the problem, where a gold standard is simply not available. 
However, several approaches could have been taken to help place the results 
in context and improve confidence that what we are seeing is real. Some 
thoughts are below. 
  
R1.9. To be clear, we provide other forms of validation apart from the 
comparison to a subtypes-only and stages-only model that substantially 
increase confidence in the results: cross- validation of the subtype 
progression patterns (both datasets), comparison of subtypes estimated 
without knowledge of FTD genotype to their actual FTD genotype (GENFI), 
reproducibility of the results in subsets of the data (GENFI), validation in an 
independent dataset (ADNI), predictive utility of both subtypes and stages 
(ADNI). All are strong forms of model validation.  
Nevertheless, in response to the reviewer’s comments below, the revised 
manuscript now includes a detailed simulation study to provide further 
validation of the ability of SuStaIn to estimate subtypes and stages – see 
Results: Synthetic data and Supplementary Material: Simulations.  
  
2. A simulation exercise should be undertaken, where artificial biomarker 
trajectories could be constructed using the likelihood function proposed, and 
then add relevant noise and other uncertainties. It would be convincing if the 
inference algorithm could correctly estimate all clusters and stages on this 
artificial data. In such an approach error rates, MSE, AUC etc can be readily 
calculated. 
  
R1.10. As mentioned above, we have performed the simulation study 
suggested by the reviewer – see Results: Synthetic data and Supplementary 
Material: Simulations. The results demonstrate and quantify the ability of the 
SuStaIn algorithm to recover subtypes and stages under a variety of different 
conditions: varying subject numbers, numbers of biomarkers, numbers of 
subtypes, as well as scenarios that violate the assumptions of the SuStaIn 
model: biomarker covariance, and the presence of a wide spread of 
progression patterns. The results provide strong additional evidence of the 
validity of the subtypes we present on the patient data sets. 
  
3. Similar to #3 above, a plot of performance with respect to increasing 
dimensionality (e.g. cluster number, number of temporal events N, etc) should 
be given, and an objective criterion of model evidence (e.g. Bayesian or Aikike 
information, MDL, etc) provided. This will help the reader understand, for 
instance, what is the level of evidence supporting the existence of exactly 4 
clusters in GENFI and exactly 3 in AD. What happens when you change other 
hard-wired parameters (N, I, C_max)? 
  
R1.11. These simulations are now included in the manuscript – see Results: 
Synthetic data and Supplementary Material: Simulations. We demonstrate that 
the performance – including the ability to estimate the correct number of 




4. Identifiability: this term was used in too loose a sense, in my opinion, based 
simply on Fig 5. There are numerical measures of identifiability that should be 
reported, if indeed the authors wish to claim this point. 
  
R1.12. We take the point here that this word has a strong meaning in 
Bayesian modeling, which was not what we intended here. We have thus 
changed our terminology throughout the manuscript to talk instead about 
assignability of subjects to subtypes (see lines 147 in Introduction, 254-270 in 
Results and 345, 427, 457-466, 472 in Discussion). Further, we make the 
concept more quantitiative by defining a metric of strength of assignment of an 
individual to subtype (see Methods: Mathematical Modelling: Strength of 
assignment to subtype lines 796-804). 
  
In summary, the present work is potentially a very important contribution to the 
field of neuroimaging and neurodegeneration, but several aspects require 
better justification and a more thorough exercising of the results. In view of 
these points, I would consider its impact to be promising but unvalidated. 
  
R1.13. Thank you for the thorough reading and feedback. Addressing these 
comments has added substantially to confirming the validity and importance of 




Reviewer #3 (Remarks to the Author): 
  
The authors apply machine learning to MRI datasets obtained from patients 
diagnosed with FTD and AD. They appear to have generated a model that will 
distinguish the various genetic forms of FTD from each other, and the various 
subtypes of AD from each other. They also claim to identify two subtypes 
within one genetic form of FTD relating to the rate of progression. Overall, 
while I do find that there are some potentially useful pieces of information in 
this manuscript, it is rather densely presented meaning that it may not have 
appeal to the general reader and may be more appropriate in a more 
specialized journal. 
 
R3.1. We believe the notion of identifying disease subtypes and 
demonstrating their utility for precision medicine has very wide appeal and 
application. Moreover, the potential of big-data analytics in healthcare is high 
in the general scientific consciousness at present; this work represents a 
unique and substantial advance in our capability to derive new disease 
understanding from such approaches. It has very wide potential application – 
to the full spectrum of chronic diseases and beyond – so will be of interest to a 
broad cross-section of the scientific community. Nevertheless, we agree there 
were a few dense paragraphs in the main text and have endeavored 
throughout to move unnecessary technical detail to the Methods or 
Supplement to enhance accessibility.  
 
There are aspects of this manuscript that do not reflect the typical clinical 
scenario. For example, they use MRI to identify subjects carrying specific 
mutations, but most patients are genetically screened for these mutations at 
the time of presentation, so it is not clear how useful it would be to apply this 
machine learning approach to identify genetic mutations carriers when either 
this information is already known or can be much more easily obtained by 
doing a simple genetic test. Thus, the clinical utility of this approach is unclear. 
  
R3.2. We believe this comment arises from a misunderstanding of the key 
message of the manuscript and the role of the FTD results in supporting it. 
The primary aim is to introduce a new method, SuStaIn, for identifying and 
characterizing disease subtypes from large cross-sectional data sets and to 
demonstrate its potential in timely applications. 
The GENFI dataset experiments, which the comment above refers to, are not 
intended to demonstrate clinical utility, but rather to provide a validation of 
SuStaIn’s ability to uncover known subtypes and their progression patterns. In 
fact, some new clinical utility does arise from the GENFI models both in 
temporal staging (not possible with genetics) and as the analysis reveals (for 
the first time) within-genotype subtypes. However, the main intended clinical 
utility arising directly from the presented results is in Alzheimer’s disease, 
where SuStaIn offers new capability for assigning individuals to subtypes and 
stages in vivo, with numerous applications, e.g. for selection of cohorts in 
clinical trials or for precision treatment assignment.  
Although we tried to make the roles of these different results clear in the 
original manuscript, the message was perhaps clouded by the fact that novel 
findings also emerge from the GENFI analysis. We have now revised several 
key sentences in the manuscript to clarify that the experiments demonstrating 
the ability of MRI to distinguish genotype are intended as a validation – see 
lines 40-42, 137-145, 172-175, 213-216, 274-277, 329-333, 342-343, 469-471 
– while the ADNI results demonstrate clinical utility – see lines 145-152, 249-
252, 311-323, 345-348, 469-471. 
  
The authors may be overstating the novelty of their data. It has long been 
known that GRN mutations produce an asymmetrical pattern of atrophy, that 
MAPT mutations affect temporal lobes (usually not as asymmetrically), and 
that C9orf72 related findings are typically widespread and affect cortex and 
subcortical structures. 
  
R3.3. We did not intend to claim these facts as novel findings of our study. 
The novel findings in FTD are the details of the temporal evolution of these 
patterns, as well as the presence of distinct within-genotype progression 
patterns. However, the key novel findings are in AD not FTD. We have revised 
several sentences in the manuscript to make this clear (in the Summary – see 
lines 40-42, Introduction – see lines 137-145 and Results – see lines 172-175, 
213-216 and Discussion – see lines 329-333, 353-356, 358-362). 
  
It is sometimes difficult to follow exactly what the authors did. For example, it 
is not clear how many samples were analyzed by their algorithm to generate 
their model. Did they include normal, pre-symptomatic, or was it just confined 
to symptomatic cases? These numbers should be include in the first 
paragraph of the Results section. However, even if all cases were included, 
then the number of symptomatic cases is still small (e.g. 14 patients carrying 
GRN mutations, 24 patients carrying C9, 11 MAPT, 117 AD cases). This is 
likely too small to generate robust results. 
  
R3.4. We have clarified the subject numbers in the manuscript (see Methods: 
Experiments: lines 830-832 and 844-845 and Supplementary Material: Table 
S3) and included them in the first paragraph of the results section as the 
reviewer suggests (see Results: lines 176,179-180,180-181,183-184).  
To clarify the algorithm takes into account all samples in each dataset and is 
able to leverage information from those in prodromal disease stages, meaning 
that the number of subjects supporting the GENFI and ADNI results is much 
greater than the reviewer thought. The GENFI results are derived from the 
data from all 172 carriers; and the ADNI results are derived from all 793 
individuals in the 3T dataset (524 with MCI or AD, in which you would expect 
to see imaging changes, and a further 269 CN, some of whom may also have 
prodromal imaging changes), and validated using 576 individuals in the 1.5T 
dataset (396 with MCI or AD, and 180 CN).  
As discussed in R1.9, we have now included extensive simulation results – 
see Supplementary Material: Simulations – that verify the ability of SuStaIn to 
estimate meaningful subtype progression patterns for datasets of the size of 
GENFI and ADNI. Of course, it would be preferable to have a larger dataset in 
the case of FTD. However, in addition to the simulation results, several other 
validation steps strongly support the findings: cross-validation, reproducibility 
in subsets of the dataset, ability to classify genotype, and general agreement 
with previous results as pointed out by the reviewer in their previous point.  
 
With respect to the 117 AD cases, was the diagnosis established 
pathologically for all of them? It is known that the clinical diagnosis of AD is 
inaccurate in 15% of cases, so if the diagnosis of AD was based on clinical 
presentation, did you allow for this inaccuracy in your model? 
  
R3.5. The ADNI AD subjects are not pathologically confirmed. We now 
include as part of the added simulation study experiments that verify the ability 
of the algorithm to determine the subtype progression patterns in the 
presence of small to moderate proportions of misdiagnosed subjects (see 
Supplementary Material: Simulations: Results: Misdiagnosis and Figures S9 
and S10).  
  
The programming code used to generate the model as well as the final model 
should be made available in the supplemental material so that others can test 
it and add to it as more data becomes available. 
  
R3.6. We will make the code available once the manuscript is published. This 
is standard practice in our group; see https://github.com/ucl-mig. 
REVIEWERS' COMMENTS:  
 
Reviewer #1 (Remarks to the Author):  
 
This revision by Young et al has substantially addressed many although not all reviewer 
comments. Explanatory text has been added, and is for the most part appropriate and 
targeted to the critiques. Most importantly, a large new simulation study is now being 
reported in SI, which demonstrates desirable properties of the algorithm, like convergence, 
robustness to errors, covariance amongst biomarkers, etc. These simulations are especially 
useful because the proposed algorithms are largely heuristic, with no optimality guarantees. 
The revision has also fully addressed one of my key issues, of model selection and the use 
of criteria such as Bayesian or information criteria. They have instead used cross validation 
to achieve the same purpose, and this is appropriate.  
 
I believe in view of these substantial changes and clarifications, and the sophistication of 
the original approach, this revision merits consideration for possible publication.  
 
One additional suggestion I would add, if the editors find it appropriate, is that the authors 
add a clear table of exactly which biomarkers are used - a full list of all demographic, tissue, 
cognitive and regional atrophy biomarkers should be listed. This critical information is very 




Reviewer #3 (Remarks to the Author):  
 
I have no further comments.  
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Reviewer #1 (Remarks to the Author): 
 
This revision by Young et al has substantially addressed many although not 
all reviewer comments. Explanatory text has been added, and is for the most 
part appropriate and targeted to the critiques. Most importantly, a large new 
simulation study is now being reported in SI, which demonstrates desirable 
properties of the algorithm, like convergence, robustness to errors, covariance 
amongst biomarkers, etc. These simulations are especially useful because the 
proposed algorithms are largely heuristic, with no optimality guarantees. The 
revision has also fully addressed one of my key issues, of model selection and 
the use of criteria such as Bayesian or information criteria. They have instead 
used cross validation to achieve the same purpose, and this is appropriate.  
 
I believe in view of these substantial changes and clarifications, and the 
sophistication of the original approach, this revision merits consideration for 
possible publication.  
 
One additional suggestion I would add, if the editors find it appropriate, is that 
the authors add a clear table of exactly which biomarkers are used - a full list 
of all demographic, tissue, cognitive and regional atrophy biomarkers should 
be listed. This critical information is very poorly presented in the current 
version, especially of the regional biomarkers.  
 
Thank you for your constructive feedback on the manuscript. We have added 
the additional table of biomarkers suggested – see Supplementary Table 4. 
 
Reviewer #3 (Remarks to the Author): 
 
I have no further comments. 	  
